Targeted Therapies in Neuroendocrine Tumors

0 Views
administrator
administrator
07/13/23

The clinical benefit of targeted therapies in neuroendocrine tumors (NETs) has primarily been restricted to the pancreatic type. However, clinical trials are currently under way examining the mTOR inhibitor everolimus in a broader patient population.

For more from this discussion, visit http://www.onclive.com/peer-exchange/nets

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next